Path: /clinical-trials/arc-im-adaptive-neurostimulation-parkinsons
Title: ARC-IM Adaptive Neurostimulation for Parkinson's Disease
Tags: section:clinical-trials, kind:clinical-trial, phase:phase-1-2, intervention:adaptive-dbs
| Attribute |
Value |
| Trial ID |
NCT06295614 |
| Sponsor |
EPFL / Neuroloop Collaboration |
| Phase |
Phase 1/2 |
| Status |
Recruiting |
| Condition |
Parkinson's Disease |
| Intervention |
ARC-IM Adaptive Neurostimulator |
| Enrollment |
20 participants (estimated) |
| Start Date |
2024 |
| Estimated Completion |
2027 |
Traditional deep brain stimulation (DBS) delivers constant high-frequency electrical pulses to brain regions like the subthalamic nucleus (STN) or globus pallidus interna (GPi). While effective, conventional DBS has significant limitations:
- One-size-fits-all stimulation: Fixed parameters don't adapt to individual patient needs or daily fluctuations
- Side effects: Can cause speech difficulties, gait impairment, or cognitive issues
- Battery consumption: Continuous stimulation reduces device longevity, requiring frequent replacements
- Disease progression: Static parameters don't account for evolving symptoms over time
- Over-stimulation: Constant stimulation can cause tolerance and reduced efficacy over time
Adaptive (or closed-loop) DBS represents a paradigm shift in neurostimulation therapy. Instead of delivering constant stimulation, adaptive systems monitor neural biomarkers in real-time and adjust stimulation parameters dynamically.
Key advantages:
- Personalized: Responds to individual patient physiology and symptom fluctuations
- Efficient: Only stimulates when needed, reducing overall energy delivery
- Reduced side effects: Lower time-averaged stimulation intensity
- Disease-responsive: Adapts to daily medication fluctuations and long-term progression
The most validated biomarker for adaptive DBS is pathological beta frequency activity (13-35 Hz) in the subthalamic nucleus. Key findings:
- Elevated beta power correlates with bradykinesia and rigidity
- Levodopa reduces beta activity, explaining its therapeutic effect
- Beta suppression precedes movement, allowing predictive stimulation
- Excessive beta predicts dyskinesia development
This biomarker provides a real-time window into the patient's motor state, enabling the adaptive system to deliver precisely targeted therapy.
The ARC-IM system represents cutting-edge neuroengineering designed for adaptive stimulation:
- Implantable pulse generator: Custom-designed miniaturized device optimized for adaptive operation
- Sensing electrodes: High-resolution arrays for recording local field potentials (LFPs)
- Processing algorithm: On-board machine learning for real-time biomarker detection
- Adaptive controller: Closed-loop system for dynamic parameter adjustment
- External controller: Patient and physician interface for monitoring and adjustment
flowchart TD
A["Sensing Electrodes"] --> B["LFP Signal Acquisition"]
B --> C["Digital Signal Processing"]
C --> D["Beta Detection Algorithm"]
D --> E["Biomarker Quantification"]
E --> F{"Stimulation Decision"}
F -->|"Beta HIGH"| G["Increase Stimulation"]
F -->|"Beta LOW"| H["Reduce Stimulation"]
G --> I["Adaptive Pulse Generator"]
H --> I
I --> J["Therapeutic Delivery"]
J --> K["Brain Target - STN/GPi"]
L["Patient Controller"] <--> M["Clinician Interface"]
M --> I
style A fill:#e1f5fe,stroke:#333
style F fill:#f9c,stroke:#333
style K fill:#c8e6c9,stroke:#333
- Neural sensing: Device continuously records LFPs from the target brain region (STN or GPi)
- Biomarker detection: On-board algorithm identifies pathological beta oscillations
- State classification: System classifies current motor state (ON/medication, OFF/medication, dyskinesia)
- Adaptive control: Stimulation parameters are adjusted based on biomarker amplitude
- Closed-loop feedback: Continuous optimization in real-time, adapting to moment-to-moment changes
| Biomarker |
Frequency |
Clinical Correlation |
| Beta oscillations |
13-35 Hz |
Bradykinesia, rigidity |
| Theta activity |
4-8 Hz |
Tremor |
| Gamma activity |
35-100 Hz |
Dyskinesia |
| Alpha activity |
8-13 Hz |
Attention, cognition |
Design: First-in-human, open-label, safety and efficacy study
Objectives:
- Primary: Safety and tolerability of the ARC-IM system
- Secondary: Comparison of adaptive vs. conventional DBS
- Exploratory: Long-term outcomes and biomarker validation
- Condition: Parkinson's disease with motor complications
- Eligibility: Indication for DBS surgery with inadequate response to medication
- Size: 20 participants
The trial employs a staged approach:
- Acute phase: Test adaptive vs. conventional stimulation in laboratory setting
- Chronic phase: 12-month home use of adaptive stimulation
- Comparison phase: Randomized crossover between adaptive and conventional modes
Inclusion criteria:
- PD diagnosis with motor complications (≥5 years)
- Inadequate response to levodopa (ON/OFF fluctuations or dyskinesias)
- Indication for DBS surgery (age 40-75, no cognitive impairment)
- Adequate response to levodopa (≥30% improvement in UPDRS)
- Able to comply with study procedures
Exclusion criteria:
- Significant cognitive impairment (MoCA <24)
- Psychiatric comorbidities (depression, psychosis)
- Previous DBS surgery
- Brain abnormalities on MRI
- Metal implants incompatible with MRI
- Active infection or autoimmune condition
- Device-related serious adverse events
- Surgical complications (infection, hemorrhage)
- Hardware failures or malfunctions
- Battery longevity
- Motor symptoms (MDS-UPDRS Part III) with adaptive vs. conventional DBS
- Time in "ON" state (good symptom control)
- Levodopa equivalent dose reduction
- Stimulation-related side effects
- Quality of life (PDQ-39)
- Neurocognitive function
- Long-term biomarker patterns
- Algorithm refinement data
- Device evolution tracking
- Home vs. laboratory performance
- Superior symptom control: Better motor scores vs. conventional DBS through optimized stimulation
- Reduced side effects: Lower time-averaged stimulation intensity with fewer speech/gait issues
- Lower battery consumption: Adaptive stimulation extends device lifespan
- Personalized therapy: Continuous optimization to individual patient needs
- Long-term efficacy: Reduced tolerance development compared to constant stimulation
¶ Challenges and Risks
- Technical complexity: More sophisticated hardware increases failure risk
- Surgical risks: Same as conventional DBS plus additional implant components
- Algorithm validation: Requires extensive testing to ensure reliability
- Regulatory pathways: Novel technology requires extensive safety documentation
- Cost: Advanced technology may be more expensive than conventional DBS
The École Polytechnique Fédérale de Lausanne is a leading Swiss research institution known for neurotechnology innovation:
- Brain Mind Institute: Leading research in neuroscience and brain function
- Center for Neuroprosthetics: Pioneering work in neural interfaces and brain-machine interfaces
- Expertise: Decades of experience in neural signal processing, machine learning for biomedical applications
Neuroloop GmbH is a medical device company specializing in:
- Implantable neurostimulation systems
- Closed-loop control algorithms
- Biomedical signal processing
- FDA/EMA regulatory pathways
| System |
Developer |
Biomarker |
Status |
Notes |
| ARC-IM |
Neuroloop/EPFL |
Beta LFP |
Phase 1/2 |
Closed-loop, fully implantable |
| Percept PC |
Medtronic |
Beta LFP |
Approved |
Sensing-enabled, not fully adaptive |
| Summit RC+S |
Boston Scientific |
Multi-band |
Research |
Research platform |
| Activa PC+S |
Abbott |
Custom |
Research |
Customizable sensing |
Relevance: MODERATE for atypical parkinsonism
While the current trial focuses on Parkinson's disease, adaptive DBS technology may have broader applications for movement disorders including:
- Progressive supranuclear palsy: Falls and rigidity may respond to adaptive GPi stimulation
- Corticobasal degeneration: Motor symptoms could potentially benefit from personalized stimulation
- Dystonia: Adaptive stimulation may provide better outcomes than conventional DBS
However, the specific ARC-IM trial is for classic Parkinson's disease with confirmed alpha-synuclein pathology, which differs from this patient's condition.